473 related articles for article (PubMed ID: 30345790)
1. Tildrakizumab: A Review of Phase II and III Clinical Trials.
Kolli SS; Gabros SD; Pona A; Cline A; Feldman SR
Ann Pharmacother; 2019 Apr; 53(4):413-418. PubMed ID: 30345790
[TBL] [Abstract][Full Text] [Related]
2. Risankizumab for the Treatment of Moderate to Severe Plaque Psoriasis.
Li W; Ghamrawi R; Haidari W; Feldman SR
Ann Pharmacother; 2020 Apr; 54(4):380-387. PubMed ID: 31672037
[No Abstract] [Full Text] [Related]
3. Tildrakizumab for the treatment of psoriasis.
Sinclair R; Thirthar Palanivelu V
Expert Rev Clin Immunol; 2019 Jan; 15(1):5-12. PubMed ID: 30394141
[No Abstract] [Full Text] [Related]
4. Safety of tildrakizumab for moderate-to-severe plaque psoriasis: pooled analysis of three randomized controlled trials.
Blauvelt A; Reich K; Papp KA; Kimball AB; Gooderham M; Tyring SK; Sinclair R; Thaçi D; Li Q; Cichanowitz N; Green S; La Rosa C
Br J Dermatol; 2018 Sep; 179(3):615-622. PubMed ID: 29742274
[TBL] [Abstract][Full Text] [Related]
5. Tildrakizumab versus placebo or etanercept for chronic plaque psoriasis (reSURFACE 1 and reSURFACE 2): results from two randomised controlled, phase 3 trials.
Reich K; Papp KA; Blauvelt A; Tyring SK; Sinclair R; Thaçi D; Nograles K; Mehta A; Cichanowitz N; Li Q; Liu K; La Rosa C; Green S; Kimball AB
Lancet; 2017 Jul; 390(10091):276-288. PubMed ID: 28596043
[TBL] [Abstract][Full Text] [Related]
6. Anti-interleukin-23 for psoriasis in elderly patients: guselkumab, risankizumab and tildrakizumab in real-world practice.
Ruggiero A; Fabbrocini G; Cinelli E; Ocampo Garza SS; Camela E; Megna M
Clin Exp Dermatol; 2022 Mar; 47(3):561-567. PubMed ID: 34642965
[TBL] [Abstract][Full Text] [Related]
7. Tildrakizumab for the treatment of psoriasis.
Bangert C; Kopp T
Immunotherapy; 2018 Sep; 10(13):1105-1122. PubMed ID: 30081696
[TBL] [Abstract][Full Text] [Related]
8. Tildrakizumab (MK-3222), an anti-interleukin-23p19 monoclonal antibody, improves psoriasis in a phase IIb randomized placebo-controlled trial.
Papp K; Thaçi D; Reich K; Riedl E; Langley RG; Krueger JG; Gottlieb AB; Nakagawa H; Bowman EP; Mehta A; Li Q; Zhou Y; Shames R
Br J Dermatol; 2015 Oct; 173(4):930-9. PubMed ID: 26042589
[TBL] [Abstract][Full Text] [Related]
9. Indirect comparisons of ixekizumab versus three interleukin-23 p19 inhibitors in patients with moderate-to-severe plaque psoriasis - efficacy findings up to week 12.
Gottlieb AB; Saure D; Wilhelm S; Dossenbach M; Schuster C; Smith SD; Ramot Y; Thaçi D
J Dermatolog Treat; 2022 Feb; 33(1):54-61. PubMed ID: 32299269
[TBL] [Abstract][Full Text] [Related]
10. Tildrakizumab: A Review in Moderate-to-Severe Plaque Psoriasis.
Frampton JE
Am J Clin Dermatol; 2019 Apr; 20(2):295-306. PubMed ID: 30924030
[TBL] [Abstract][Full Text] [Related]
11. Tildrakizumab: monoclonal antibody against IL-23p19 for moderate to severe psoriasis.
Paton DM
Drugs Today (Barc); 2018 Jul; 54(7):433-444. PubMed ID: 30090880
[TBL] [Abstract][Full Text] [Related]
12. Treating Moderate-to-Severe Plaque Psoriasis With Guselkumab: A Review of Phase II and Phase III Trials.
Howell ST; Cardwell LA; Feldman SR
Ann Pharmacother; 2018 Apr; 52(4):380-387. PubMed ID: 29134822
[TBL] [Abstract][Full Text] [Related]
13. Systematic review of interleukin-12, interleukin-17, and interleukin-23 pathway inhibitors for the treatment of moderate-to-severe chronic plaque psoriasis: ustekinumab, briakinumab, tildrakizumab, guselkumab, secukinumab, ixekizumab, and brodalumab.
Tausend W; Downing C; Tyring S
J Cutan Med Surg; 2014; 18(3):156-69. PubMed ID: 24800703
[TBL] [Abstract][Full Text] [Related]
14. Effect of tildrakizumab (MK-3222), a high affinity, selective anti-IL23p19 monoclonal antibody, on cytochrome P450 metabolism in subjects with moderate to severe psoriasis.
Khalilieh S; Hussain A; Montgomery D; Levine V; Shaw PM; Bodrug I; Mekokishvili L; Bailey-Smith C; Glasgow XS; Cheng A; Martinho M; Iwamoto M
Br J Clin Pharmacol; 2018 Oct; 84(10):2292-2302. PubMed ID: 29926968
[TBL] [Abstract][Full Text] [Related]
15. Safety of selective IL-23p19 inhibitors for the treatment of psoriasis.
Crowley JJ; Warren RB; Cather JC
J Eur Acad Dermatol Venereol; 2019 Sep; 33(9):1676-1684. PubMed ID: 31054215
[TBL] [Abstract][Full Text] [Related]
16. Selective Interleukin-23 p19 Inhibition: Another Game Changer in Psoriasis? Focus on Risankizumab.
Torres T
Drugs; 2017 Sep; 77(14):1493-1503. PubMed ID: 28770513
[TBL] [Abstract][Full Text] [Related]
17. The potential utility of tildrakizumab: an interleukin-23 inhibitor for the treatment of psoriasis.
Yiu ZZ; Warren RB
Expert Opin Investig Drugs; 2017 Feb; 26(2):243-249. PubMed ID: 28042732
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and safety of tildrakizumab in Japanese patients with moderate to severe plaque psoriasis: Results from a 64-week phase 3 study (reSURFACE 1).
Igarashi A; Nakagawa H; Morita A; Okubo Y; Sano S; Imafuku S; Tada Y; Honma M; Mendelsohn AM; Kawamura M; Ohtsuki M
J Dermatol; 2021 Jun; 48(6):853-863. PubMed ID: 33630387
[TBL] [Abstract][Full Text] [Related]
19. Tildrakizumab: First Global Approval.
Markham A
Drugs; 2018 Jun; 78(8):845-849. PubMed ID: 29752706
[TBL] [Abstract][Full Text] [Related]
20. Tildrakizumab for treating psoriasis.
Galluzzo M; D'adamio S; Bianchi L; Talamonti M
Expert Opin Biol Ther; 2017 May; 17(5):645-657. PubMed ID: 28271735
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
